Recruiting

Understanding How Immune Therapy Works in Advanced Liver Cancer

Plain-English translation of NCT07186010 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This research study is designed to help doctors better understand how immune therapy works in patients with advanced liver cancer. By collecting blood samples and tumor tissue from participants over time, researchers hope to identify biological markers—like patterns in your genes and immune cells—that can predict whether the treatment will work well for you and help guide future personalized treatment decisions.

Currently, doctors cannot easily predict which patients with advanced liver cancer will respond well to immune therapy and which will not. This trial aims to find biological clues in blood and tumor tissue that could help doctors choose the best treatment strategy for each patient and improve outcomes in this serious condition.

Do you qualify?

You likely qualify if…

you have been diagnosed with hepatocellular carcinoma (liver cancer) that is confirmed by a biopsy
your liver cancer is advanced, has come back after treatment, or has spread to other parts of your body
your cancer cannot be treated with surgery, liver transplant, or other local procedures
you are scheduled to receive immune therapy as your treatment

You likely don't qualify if…

you have a rare type of liver cancer called fibrolamellar or sarcomatoid hepatocellular carcinoma
you have another type of cancer at the same time
your liver cancer is early-stage enough to be treated with surgery, transplant, or radiofrequency ablation
you have other conditions or circumstances that might interfere with the study results

What participation looks like

If you join this study, you will have blood samples drawn before you start immune therapy, and then again at 6, 12, 24, and 48 weeks after treatment begins, as well as if your cancer progresses. You may also have a tumor tissue sample collected through a biopsy procedure. These samples will be analyzed to look for biological markers that could help predict how well the treatment works for you. The study involves approximately 50 participants and lasts as long as your treatment continues.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(1 site)

South Korea

Asan Medical Center, Seoul, Song-pa